Clinical Trial Update: Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005) [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated a human papillomavirus type 16 vaccine (V501-005) for preventing HPV-16 infection in females aged 16–23; the trial is completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• HPV-16 vaccine (V501-005) (Human papillomavirus type 16 vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HPV 16 Infection | Phase 2 | Status: COMPLETED | Results posted: 2010-04-09